No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
326 |
4. Check minimum number of eventsNone |
326 |
5. Include endpointsNone |
326 |
6. Filter based on genotype QC (FinnGen only) |
295 |
Control definitions (FinnGen only)
- Control exclude
- G6_MYONEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G71
- Name in latin
- Morbositates myotonicae
Similar endpoints
↥List of similar endpoints to
Myotonic disorders
based on the number of shared cases.
Similar with more cases:
- Diseases of the myoneural junction and muscle
- Neurological diseases
- Neurological diseases, wide definition
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2311 | 1166 | 1126 |
| Only index persons | 1965 | 1019 | 946 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.03 |
| Only index persons | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 44.33 | 44.69 | 43.83 |
| Only index persons | 43.13 | 43.84 | 42.36 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 295 | 173 | 122 |
| Unadjusted period prevalence (%) | 0.06 | 0.06 | 0.06 |
| Median age at first event (years) | 48.11 | 48.07 | 48.16 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 309
- Matched controls
- 3090
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G71.18
ICD-10 Finland
Other myotonic disease
+∞
145.7
128
*
G71.11
ICD-10 Finland
Dystrophia myotonica [Steinert]
+∞
135.7
120
*
Z31.5
ICD-10 Finland
Genetic counselling
19.2
133.2
126
107
G71.12
ICD-10 Finland
Myotonia congenita
+∞
123.4
110
*
G72.9
ICD-10 Finland
Myopathy, unspecified
548.3
48.8
47
*
R1250
NOMESCO Finland
Evaluation of functional capability
12.6
40.6
42
38
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.3
36.5
71
139
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
+∞
32.9
31
*
G71.08
ICD-10 Finland
Other muscular dystrophy
+∞
29.7
28
*
G71.8
ICD-10 Finland
Other primary disorders of muscles
+∞
29.7
28
*
G71.1
ICD-10 Finland
Myotonic disorders
307.9
28.2
28
*
L28
ICPC
Limited function/disability (L)
4.2
26.1
89
274
N99
ICPC
Neurological disease other
30.0
22.7
30
11
SPAT1215
SPAT
Assessment of need for medical rehabilitation
7.2
20.4
32
49
XF404
NOMESCO Finland
Ambulatory ECG
4.6
19.1
50
124
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.5
19.1
40
82
H26.02
ICD-10 Finland
Presenil cataract
8.4
18.6
25
32
N03AF01
ATC
carbamazepine; oral, rectal
5.4
18.1
38
78
N03AX09
ATC
lamotrigine; oral
5.0
17.9
42
95
G71.00
ICD-10 Finland
Muscular dystrophy benign [Becker]
+∞
17.9
17
*
C01BB02
ATC
mexiletine; systemic
190.5
17.7
18
*
N03AE01
ATC
clonazepam; systemic
4.9
15.9
37
83
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
157.1
14.6
15
*
J96.1
ICD-10 Finland
Chronic respiratory failure
15.4
14.3
23
16
L19
ICPC
Muscle symptom/complaint NOS
6.3
13.7
24
41
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.0
13.6
73
290
G71.28
ICD-10 Finland
Other congenital myopathy
+∞
12.6
12
*
SPAT1229
SPAT
Assessment of need for aid
4.5
12.4
32
78
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.8
12.3
41
121
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.5
12.1
110
567
G71.0
ICD-10 Finland
Muscular dystrophy
+∞
11.5
11
*
3592A
ICD-9 Finland
Muscular dystrophies and other myopathies, Myotonic disorders
+∞
11.5
11
*
N29
ICPC
Neurological sympt/complt other
11.2
11.5
21
20
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.9
11.2
58
225
Z3226
NOMESCO Finland
Physiotherapist
2.7
11.1
74
327
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.5
11.0
90
439
XA800
NOMESCO Finland
Neuropsychological investigation
3.9
10.6
32
88
G71.14
ICD-10 Finland
Paramyotonia congenita
+∞
10.5
10
*
NXL00
NOMESCO Finland
Biopsy of muscle
+∞
10.5
10
*
RF410, ,
NOMESCO Finland
19.6
10.4
15
8
RF420, ,
NOMESCO Finland
15.3
10.1
16
11
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
4.5
10.0
25
59
R42
ICD-10 Finland
Dizziness and giddiness
2.5
10.0
79
378
H26.4
ICD-10 Finland
After-cataract
3.5
9.8
35
108
G72.8
ICD-10 Finland
Other specified myopathies
56.8
9.7
11
*
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
3.3
9.6
38
125
R4120
NOMESCO Finland
Occupational therapy
3.4
9.2
35
112
RF210, ,
NOMESCO Finland
5.1
9.0
19
39
K80.2
ICD-10 Finland
Calculus of gallbladder without cholecystitis
2.8
8.7
48
191
N03AX12
ATC
[U] gabapentin; oral
2.4
8.4
65
306
N28
ICPC
Limited function/disability (N)
9.9
8.4
16
17
33098
ICD-8 Finland
Hereditary neuromuscular disorders, Alii definiti
+∞
8.4
8
*
R4110
NOMESCO Finland
Physiotherapy
2.1
8.3
98
550
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
4.4
8.3
21
50
L99
ICPC
Musculoskeletal disease other
7.2
8.2
19
28
A28
ICPC
Limited function/disability NOS
2.6
8.1
50
211
G47.3
ICD-10 Finland
Sleep apnoea
2.2
8.0
90
495
N03AX16
ATC
[U] pregabalin
2.2
7.8
83
447
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.1
7.5
90
506
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
2.1
7.4
80
432
Z82.6
ICD-10 Finland
Family history of arthritis and other diseases of the musculoskeletal system and connective tissue
+∞
7.3
7
*
G71.10
ICD-10 Finland
Myotonia drug-induced
+∞
7.3
7
*
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
3.5
7.3
26
80
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
7.6
7.3
16
22
RF120, ,
NOMESCO Finland
12.4
7.1
12
10
R4110, ,
SPAT
2.4
7.0
53
246
Z3231
NOMESCO Finland
Registered nurse
2.0
6.9
93
544
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.6
6.8
42
177
N06AX21
ATC
duloxetine; oral
2.4
6.6
51
239
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
3.8
6.6
20
55
M03BX01
ATC
baclofen; systemic
5.9
6.6
17
30
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
71.3
6.4
7
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.1
6.4
66
348
M79.1
ICD-10 Finland
Myalgia
2.2
6.4
62
319
G71.3
ICD-10 Finland
Mitochondrial myopathy, not elsewhere classified
+∞
6.3
6
*
H28.2*G71.11
ICD-10 Finland
Myotonic cataract
+∞
6.3
6
*
TNX05
NOMESCO Finland
Simple incision of soft tissue, unspecified region
+∞
6.3
6
*
Z95.0
ICD-10 Finland
Presence of electronic cardiac devices
3.9
6.2
18
48
R5110, ,
SPAT
2.8
6.1
31
118
R03AC02
ATC
salbutamol; inhalant
1.8
6.0
184
1383
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
184
788
4.30
35.46
3.4
2.1
295.39
172.87
u/l
1.68
176
752
133
666
2.75
16.44
3.0
3.3
850.32
934.62
ng/l
0.10
112
558
197
1254
2.58
14.18
7.8
7.1
1.21
1.21
mmol/l
0.26
178
1085
68
264
3.02
13.20
9.3
8.6
12.01
12.74
kpa
0.54
68
257
68
264
3.02
13.20
9.3
8.6
5.31
5.15
kpa
0.56
68
256
65
254
2.97
12.42
9.4
8.9
1.69
0.99
mmol/l
0.68
58
216
171
1134
2.14
9.70
7.6
6.4
1.21
1.21
mmol/l
0.21
165
1053
169
1125
2.11
9.39
5.1
4.8
35.67
36.60
g/l
1.25
157
1074
42
154
3.00
8.87
1.9
3.6
129.51
118.16
ng/l
0.10
35
141
255
2034
2.45
8.45
8.2
8.1
82.41
77.88
u/l
0.73
249
1938
208
1543
2.06
8.10
6.5
4.8
6.37
6.50
mmol/l
0.47
198
1452
60
279
2.43
7.95
1.6
2.0
362.26
366.36
nmol/l
0.06
53
264
160
1090
1.97
7.86
1.9
2.0
96.08
96.22
pmol/l
0.01
87
556
76
397
2.21
7.68
2.7
2.8
2.89
2.22
e6/l
0.26
33
184
65
329
2.24
7.05
8.6
6.9
105.52
104.35
mmol/l
1.36
65
329
168
1206
1.86
6.65
2.7
2.5
77.63
75.71
nmol/l
0.36
158
1099
36
142
2.74
6.64
14.8
9.3
16.36
16.28
%
0.05
36
137
85
489
2.02
6.58
3.9
3.7
186.61
281.23
ng/l
0.35
64
341
77
434
2.03
6.28
2.6
2.7
0.58
0.87
e6/l
0.77
34
221
203
1566
1.86
6.19
7.4
10.4
3.95
3.91
e9/l
0.07
175
1378
72
410
1.99
5.66
1.8
1.9
—
—
—
0
0
107
698
1.82
5.53
1.6
1.6
19.66
20.88
nmol/l
0.47
97
594
54
287
2.07
5.10
1.8
1.8
—
—
—
0
0
10
12
8.57
5.10
3.3
4.2
29.30
33.23
umol/l
—
10
6
107
713
1.77
5.08
3.2
2.9
0.37
0.41
e6/l
0.11
70
510
98
641
1.77
4.94
2.4
2.1
2.99
2.90
mg/l
0.10
87
562
52
277
2.05
4.88
2.0
4.7
226.26
235.08
u/l
0.33
47
268
185
1451
1.69
4.71
6.7
6.4
11.06
11.06
umol/l
0.00
178
1383
238
2006
1.81
4.61
5.4
4.2
11.92
9.85
mm/h
1.40
231
1876
173
1338
1.67
4.61
3.4
3.1
114.42
118.51
ug/l
0.10
167
1263
17
54
3.27
4.56
1.2
1.1
2.41
1.71
u/ml
—
10
32
30
132
2.41
4.45
1.6
1.6
—
—
—
0
0
294
2688
2.93
4.34
23.0
15.6
140.05
139.77
mmol/l
1.24
294
2637
294
2691
2.91
4.27
23.1
15.7
3.96
3.95
mmol/l
0.32
294
2633
31
142
2.32
4.22
3.3
3.2
0.95
1.32
mmol/l
0.21
24
104
245
2104
1.79
4.19
5.1
4.4
14.51
14.58
pmol/l
0.17
233
1947
60
358
1.84
4.03
1.7
1.6
1261.66
1157.99
nmol/l
0.43
55
267
48
266
1.95
4.03
2.8
2.5
65.31
30.74
u/l
0.44
35
228
53
306
1.88
3.94
1.8
1.8
—
—
—
0
0
133
998
1.58
3.77
4.4
3.2
38.03
31.27
u/l
1.90
127
952
120
883
1.59
3.67
2.5
3.3
2.36
2.35
mmol/l
0.22
109
811
34
172
2.10
3.66
3.5
3.3
5.40
5.11
kpa
1.17
34
167
34
174
2.07
3.55
3.8
4.0
66.97
88.42
ng/l
1.44
29
157
275
2486
1.97
3.48
6.5
5.3
1.73
1.87
mu/l
1.18
266
2323
262
2335
1.80
3.45
23.1
17.3
13.67
13.46
%
1.15
262
2321
9
18
5.12
3.39
2.1
2.4
—
—
—
0
0
290
2682
2.32
3.30
18.5
13.9
19.98
21.87
mg/l
0.54
255
2151
17
66
2.67
3.27
1.3
1.1
0.47
2.17
u/ml
—
8
40
27
132
2.15
3.18
1.6
2.1
11.00
4.72
iu/ml
—
7
33
113
844
1.53
3.14
3.1
2.6
53.95
61.06
u/l
0.70
105
792
28
141
2.08
3.06
9.5
7.0
25.81
24.76
mmol/l
0.67
28
135
12
36
3.43
3.05
1.5
1.3
255.17
262.64
mu/l
0.06
12
28
29
150
2.03
2.96
6.3
4.4
24.77
24.27
mmol/l
0.31
29
150
52
328
1.70
2.88
4.3
2.5
7.14
7.56
umol/l
0.08
42
288
70
485
1.57
2.68
2.1
1.7
104918470.08
27990882.07
pmol/l
0.32
61
418
174
1455
1.45
2.62
3.7
3.5
0.00
0.01
estimate
0.50
34
283
16
69
2.39
2.53
1.3
1.3
—
1.00
—
0
7
37
222
1.76
2.45
1.9
2.0
—
—
—
0
0
172
1447
1.43
2.44
3.7
3.5
0.00
5.38
estimate
0.50
37
302
13
52
2.57
2.39
1.0
1.6
—
—
—
0
0
170
1436
1.41
2.30
3.5
3.4
0.00
0.00
estimate
-0.00
38
305
8
23
3.54
2.28
1.3
1.3
97.62
102.65
pmol/l
—
8
23
6
13
4.68
2.28
2.2
2.0
61.50
65.43
ug/l
—
6
13
32
188
1.78
2.28
1.9
1.9
—
—
—
0
0
82
608
1.47
2.27
1.5
1.9
1.21
1.09
mg/l
0.14
62
479
68
486
1.51
2.25
2.3
2.5
2.49
2.44
mmol/l
1.83
58
433
13
54
2.47
2.23
1.5
3.0
5.00
7.77
pmol/l
0.99
13
54
30
176
1.78
2.15
1.8
1.7
—
—
—
0
0
8
25
3.26
2.11
1.1
1.2
—
72.20
—
0
5
18
89
2.09
2.10
2.7
2.3
24.36
24.63
mmol/l
0.09
18
89
5
10
5.06
2.08
1.0
1.0
—
—
—
0
0
14
63
2.28
2.04
1.2
3.1
1.40
3.04
ratio
—
6
38
22
119
1.91
2.03
2.0
1.5
—
—
—
0
0
20
105
1.97
2.00
1.5
1.4
—
—
—
0
0
14
64
2.24
1.97
1.0
1.6
—
—
—
0
0
5
11
4.60
1.95
1.0
1.0
—
—
—
0
0
12
52
2.36
1.90
1.2
1.4
—
—
—
0
0
15
72
2.14
1.89
3.1
3.1
8.68
8.35
kpa
0.26
15
72
18
93
1.99
1.89
3.8
3.7
24.41
24.72
mmol/l
0.18
18
87
92
721
1.39
1.86
1.4
1.3
2.84
1.78
u/ml
0.18
22
213
19
101
1.94
1.85
1.4
1.4
—
—
—
0
0
26
154
1.75
1.83
2.6
3.8
127.88
129.95
g/l
0.16
26
149
53
376
1.49
1.82
1.6
2.2
29.78
29.24
s
0.33
48
367
296
2840
2.00
1.70
24.1
17.5
68.87
74.23
umol/l
2.65
296
2808
12
55
2.23
1.69
1.0
1.7
—
—
—
0
0
117
967
1.34
1.67
4.5
3.4
56.89
34.11
ng/l
0.51
88
614
7
25
2.84
1.66
1.0
1.0
—
—
—
0
0
7
25
2.84
1.66
1.0
1.0
—
—
—
0
0
15
77
2.00
1.62
1.0
1.9
—
—
—
0
0
267
2507
1.48
1.56
6.8
5.8
38.29
38.66
mmol/mol
0.25
260
2378
10
45
2.26
1.48
1.0
1.4
—
304.00
—
0
5
10
45
2.26
1.48
1.0
1.4
—
—
—
0
0
14
73
1.96
1.46
4.4
2.7
—
—
—
0
0
270
2548
1.47
1.46
5.3
4.7
5.91
5.83
mmol/l
0.40
257
2379
55
414
1.40
1.40
1.9
1.8
1.57
1.46
%
0.25
49
369
6
23
2.64
1.37
1.0
1.0
—
—
—
0
0
217
1986
1.31
1.37
4.5
3.3
78.77
46.05
u/l
2.78
210
1900
14
75
1.91
1.36
1.0
1.7
—
—
—
0
0
71
563
1.34
1.31
1.4
1.3
18.10
28.38
iu/ml
1.10
23
171
15
85
1.80
1.25
1.1
1.1
—
—
—
0
0
9
45
2.03
1.24
1.0
1.7
—
—
—
0
0
84
689
1.30
1.22
2.8
2.7
315.55
335.60
umol/l
1.16
74
618
270
2568
1.41
1.19
19.4
13.0
92.57
86.38
ml/min/173m2
3.19
252
2351
0
35
0.00
1.16
0.0
1.5
—
—
—
0
0
5
20
2.52
1.15
1.0
1.1
—
—
—
0
0
18
278
0.63
1.12
12.2
6.2
—
—
—
0
0
207
1906
1.26
1.12
3.5
3.3
—
—
—
0
0
98
833
1.26
1.07
2.9
2.8
0.00
0.01
estimate
0.80
34
249
7
33
2.15
1.06
1.4
1.2
—
—
—
0
0
12
68
1.80
1.02
1.7
1.8
—
—
—
0
0
14
84
1.70
0.99
1.1
1.1
—
—
—
0
0
126
1111
1.23
0.98
3.5
3.2
0.00
0.02
estimate
0.96
31
262
64
524
1.28
0.95
1.4
1.3
13.17
10.29
u/ml
0.12
28
217
95
816
1.24
0.94
4.4
4.0
16.51
9.41
mg/mmol
0.38
57
498
6
27
2.25
0.94
1.2
1.0
—
—
—
0
0
9
52
1.75
0.93
1.3
1.8
—
—
—
0
0
29
213
1.40
0.88
2.1
2.7
68.25
70.31
ml/min/173m2
0.08
12
89
91
784
1.23
0.87
3.5
3.6
0.00
0.01
estimate
0.74
36
288
13
80
1.65
0.86
1.2
1.3
284.59
306.07
ug/g
—
8
48
18
121
1.52
0.85
1.2
1.5
457.17
251.93
miu/ml
—
6
65
19
131
1.48
0.80
1.9
3.2
0.63
0.60
%
0.19
19
131
18
123
1.49
0.79
1.6
1.5
266.61
313.90
mu/l
0.57
18
113
75
642
1.22
0.76
3.8
3.5
1.02
1.02
kg/l
0.23
51
422
9
53
1.72
0.76
1.0
3.6
—
1025.33
—
0
6
58
483
1.25
0.76
1.4
1.5
—
—
—
0
0
5
24
2.10
0.75
4.4
3.0
—
—
—
0
0
138
1253
1.18
0.74
2.6
2.7
—
—
estimate
—
0
0
17
117
1.48
0.73
2.2
1.9
—
—
—
0
0
7
41
1.72
0.70
1.9
1.5
—
—
—
0
0
7
41
1.72
0.70
1.9
1.5
—
—
—
0
0
15
102
1.49
0.69
1.2
1.6
—
—
—
0
0
5
29
1.74
0.64
1.6
1.2
—
—
—
0
0
8
50
1.62
0.62
1.6
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
8
52
1.55
0.60
1.0
1.9
—
—
—
0
0
10
64
1.58
0.59
1.2
1.7
—
—
—
0
0
0
23
0.00
0.58
0.0
1.1
—
—
—
0
0
6
36
1.68
0.57
1.5
1.3
—
—
—
0
0
6
37
1.63
0.56
1.0
1.4
—
—
—
0
0
21
160
1.34
0.55
1.2
1.3
—
—
—
0
0
9
60
1.51
0.55
1.3
1.3
—
—
—
0
0
13
91
1.45
0.54
2.1
2.0
—
—
—
0
0
6
39
1.55
0.53
1.8
1.3
—
—
—
0
0
27
215
1.28
0.53
1.6
1.4
—
—
—
0
0
13
92
1.43
0.51
1.2
1.3
—
—
—
0
0
80
716
1.16
0.50
4.7
4.5
1.47
1.73
ug/l
0.56
75
649
7
45
1.57
0.49
1.3
1.4
28.56
23.68
u/l
—
7
38
10
68
1.49
0.47
1.0
1.3
—
—
—
0
0
9
127
0.70
0.44
1.2
1.1
1.64
1.56
g/l
—
9
127
228
2357
0.88
0.44
25.0
17.7
331.45
333.22
g/l
1.87
228
2346
5
31
1.62
0.43
1.6
1.2
—
—
—
0
0
5
31
1.62
0.43
1.6
1.2
—
—
—
0
0
71
638
1.15
0.43
2.1
2.3
—
—
—
0
0
5
32
1.57
0.42
1.2
1.1
—
19.48
—
0
14
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
3.3
—
1.63
—
0
16
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
10.5
—
62.17
—
0
6
5
34
1.48
0.40
1.0
2.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.0
—
—
—
0
0
21
169
1.26
0.40
1.0
1.1
—
—
—
0
0
10
71
1.42
0.39
1.3
1.6
—
—
—
0
0
128
1200
1.11
0.39
2.1
2.0
1.54
1.42
mmol/l
0.96
109
1028
12
89
1.36
0.38
1.0
1.1
—
3.68
—
0
12
5
36
1.40
0.38
1.6
1.2
—
—
—
0
0
5
36
1.40
0.38
1.0
1.1
—
—
—
0
0
6
42
1.44
0.35
1.7
1.9
13.17
13.25
%
—
6
42
6
43
1.40
0.35
1.0
1.0
—
—
—
0
0
23
191
1.22
0.34
1.1
1.4
—
34.44
—
0
18
69
630
1.12
0.33
1.7
1.6
—
—
—
0
0
261
2662
0.87
0.33
5.7
4.8
1.54
1.47
mmol/l
1.31
248
2499
46
410
1.14
0.32
2.4
2.1
—
—
—
0
0
10
130
0.76
0.30
1.9
1.1
0.79
0.92
g/l
—
10
130
14
112
1.26
0.29
4.0
3.0
1.02
1.02
ratio
0.21
14
107
8
63
1.28
0.28
1.1
1.5
—
—
—
0
0
249
2539
0.90
0.27
4.9
4.1
1.44
1.29
mmol/l
2.37
234
2373
5
38
1.32
0.23
1.0
2.2
—
—
—
0
0
28
248
1.14
0.22
3.1
3.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
0.21
—
0
11
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
10
0.00
0.21
0.0
1.0
—
143.30
—
0
10
0
10
0.00
0.21
0.0
1.0
—
60.59
—
0
10
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
12
0.00
0.21
0.0
2.0
—
117.00
—
0
12
5
43
1.17
0.21
1.0
1.1
—
—
—
0
0
11
91
1.22
0.18
2.2
1.7
—
—
—
0
0
264
2670
0.92
0.16
5.8
4.9
4.83
4.72
mmol/l
0.99
252
2525
17
150
1.14
0.15
1.9
1.6
0.41
0.35
mg/l
0.12
12
63
46
432
1.08
0.14
2.8
2.8
0.52
0.74
ug/l
2.16
28
258
5
44
1.14
0.10
1.0
1.1
—
—
—
0
0
5
44
1.14
0.10
1.0
1.1
—
—
—
0
0
5
47
1.06
0.09
1.2
1.1
—
—
—
0
0
25
233
1.08
0.09
1.4
1.3
90.94
144.23
u/ml
—
8
102
39
371
1.06
0.09
2.5
2.0
—
—
—
0
0
6
58
1.04
0.08
1.3
1.6
59.36
53.83
ug/l
—
6
58
26
247
1.06
0.06
3.2
4.7
7.03
54.21
ug/l
0.81
20
200
58
567
1.03
0.04
4.1
4.0
22.84
22.29
%
0.08
21
255
269
2700
0.97
0.03
6.2
5.5
2.79
2.79
mmol/l
0.00
256
2543
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.0
—
138.00
—
0
6
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
6.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
51
0.98
-0.00
1.0
1.1
—
13.00
—
0
9
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
49
1.02
-0.00
2.8
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
8
83
0.96
-0.00
1.3
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_MYOTDIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYOTDIS | 3.443 [2.74, 4.32] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.048 |
During the follow-up period (1.1.1998 — 31.12.2019), 168 out of 957 females with G6_MYOTDIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYOTDIS | 3.471 [2.87, 4.19] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.069 |
During the follow-up period (1.1.1998 — 31.12.2019), 219 out of 898 males with G6_MYOTDIS died.
Mortality risk
Mortality risk for people of age
years, who have G6_MYOTDIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.244% | 0.863% |
| 5 | 1.687% | 4.271% |
| 10 | 4.616% | 10.427% |
| 15 | 8.129% | 20.038% |
| 20 | 13.812% | 32.6% |
Relationships between endpoints
↥Index endpoint: G6_MYOTDIS – Myotonic disorders
GWS hits: 26
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data